Corporate / CVC · 1 deal
Every published round Novartis Venture Fund took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Aravax | Series B | 28 Jan 2024 | $66m | Participant | Startup News (WA), Forbes Australia, @AuManufacturing (28 Jan 2024), Business News Australia, Brandon BioCatalyst, Brandon Capital, @AuManufacturing (23 Jan 2024), Breakthrough Victoria, Tenmile portfolio |
Companies Novartis Venture Fund has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Aravax | Biotech company running a Phase 2 peanut allergy trial | 28 Jan 2024, Series B | 1 | 0 |
Fund closes reported for Novartis Venture Fund, as distinct from the investments it has made.
Companies Novartis Venture Fund has backed that another company then bought. An exit for the holding, not a deal Novartis Venture Fund did.
Stories naming Novartis Venture Fund. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
The US medicines regulator has granted Fast Track designation to Aravax's peanut-allergy immunotherapy PVX108, easing its development path; the Melbourne-based biotech expects Phase 2 data later in 2026.
Aravax has finished enrolling 95 young patients in its Phase 2 peanut-allergy immunotherapy trial across US and Australian sites, with results expected in the first half of 2026.
Breakthrough Victoria announces a $12 million investment in Aravax, part of a $66 million Series B, advancing the biotech's peanut allergy immunotherapy into phase two trials in Australia and the United States.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·Business News Australia·@AuManufacturing·Forbes Australia·Startup News (WA)
Australian medtech Endoluminal Sciences has licensed its technology for sealing leaks around artificial heart valves to Swiss valve maker Symetis for use in transcatheter valve products; backers of both companies are named.